Related Experiment Video

Updated: Nov 3, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

[Targeted therapies for non-small cell lung cancer : state of the art in 2021]

A Sibille1, J L Corhay1, F Vaillant1

  • 1Service de Pneumologie, CHU Liège, Belgique.

Revue Medicale De Liege
|June 3, 2021
PubMed

Insights

Identifying molecular aberrations in non-small cell lung cancer is crucial. Targeted therapies, including newer inhibitors, offer improved efficacy and tolerability for advanced lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is often diagnosed at advanced stages.
  • Specific molecular aberrations drive tumor survival in subsets of NSCLC.
  • Established targets like Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), and Repressor Of Silencing1 (ROS1) have been successfully targeted for over 15 years.

Purpose of the Study:

  • To highlight the critical role of identifying molecular aberrations in NSCLC.
  • To discuss the evolution and efficacy of targeted therapies in lung cancer treatment.
  • To emphasize the importance of molecular profiling for personalized patient care.

Main Methods:

  • Review of established and emerging molecular targets in NSCLC.
  • Analysis of targeted therapy efficacy and tolerability.
  • Discussion of diagnostic strategies for molecular aberration identification.

Main Results:

  • Newer targeted inhibitors demonstrate enhanced efficacy and better tolerability.
  • Emerging targets include Kirsten Rat Sarcoma (KRAS), Rearranged during Transfection (RET), MET, and Neurotrophic Receptor Tyrosine Kinase (NTRK).
  • Targeted therapies are increasingly benefiting NSCLC patients.

Conclusions:

  • Molecular aberration identification is essential for optimal NSCLC patient management.
  • Continuous development of targeted therapies offers improved treatment outcomes.
  • Personalized medicine approaches are transforming lung cancer care.
Keywords:
NonOncogenic driverTargeted therapyTreatmentTyrosine kinase inhibitorsMutationsmall cell lung cancer

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
797
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
595
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K